Merck, Inc.
🇺🇸United States
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 254
- Registration Number
- NCT02447003
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02411929
Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)
Phase 4
Withdrawn
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02410590
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 734
- Registration Number
- NCT02403674
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitorDrug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitorDrug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 673
- Registration Number
- NCT02397096
Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02392494
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT02387983
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Phase 3
Completed
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Biological: pembrolizumab
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 592
- Registration Number
- NCT02370498
A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344)
Phase 1
Withdrawn
- Conditions
- Heart Failure
- Interventions
- Procedure: Blood DrawProcedure: Loop Diuretic Withdrawal/Salt Load
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02364752
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Phase 3
Active, not recruiting
- Conditions
- Melanoma
- Interventions
- Biological: pembrolizumabDrug: placebo
- First Posted Date
- 2015-02-13
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1019
- Registration Number
- NCT02362594
© Copyright 2025. All Rights Reserved by MedPath